Showing results (1011-1020 of 6,501) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|November 26, 2011
Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cellsAnahid Jewett, Han-Ching TsengCancer Immunology, Immunotherapy : CII|March 6, 2012
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenaseMads Hald AndersenCancer Immunology, Immunotherapy : CII|June 1, 2011
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cellsCheryl E Myers, Paul Hanavan, Kwasi Antwi, et al.Cancer Immunology, Immunotherapy : CII|February 18, 2011
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceSally M Amos, Hollie J Pegram, Jennifer A Westwood, et al.Cancer Immunology, Immunotherapy : CII|June 18, 2011
Therapeutic effects of metformin in breast cancer: involvement of the immune system?Sarah Schott, Angelika Bierhaus, Florian Schuetz, et al.Cancer Immunology, Immunotherapy : CII|June 18, 2011
Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancerMarie-Andrée Forget, Alexandre Reuben, Simon Turcotte, et al.Cancer Immunology, Immunotherapy : CII|June 18, 2011
Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptideMitsuru Sakakibara, Tatsuya Kanto, Michiyo Hayakawa, et al.Cancer Immunology, Immunotherapy : CII|June 18, 2011
Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppressionJeremy A O'Sullivan, Andrew Zloza, Frederick J Kohlhapp, et al.Cancer Immunology, Immunotherapy : CII|October 18, 2011
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapyDaniel W Fowler, John Copier, Natalie Wilson, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1996
Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon gamma treatmentM G Ott, D N Männel, H Gallati, et al.Pageof 651